Each of our Medical Research Advisory Committee members are cancer scientists of the highest repute. They are leaders in Australian and international cancer research.
The Committee considers all applications received for ACRF grants funding, making recommendations to the Board of Trustees of ACRF as to where grants could be awarded for maximum impact and innovation in cancer prevention, diagnosis and treatment.
Procedures of the Committee include:
Membership of the ACRF Medical Research Advisory Committee is authorised by the National Health and Medical Research Council (NHMRC).
PROFESSOR ROGER REDDEL, BSC (MED), MBBS, PHD, FRACP, FAA
Chairman of the ACRF Medical Research Advisory Committee
Appointed to the MRAC in 2012. Director of Children’s Medical Research Institute (CMRI), Westmead Sydney; Sir Lorimer Dods Professor, Sydney University; Head of CMRI’s Cancer Research Unit, Director Cellbank of Australia and Co-Director of ProCan®.
PROFESSOR MICHAEL BROWN MBBS, FRACP, FRCPA
Appointed to the MRAC in 2016. Director, Cancer Clinical Trials Unit, and Senior Consultant, Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre; Clinical Professor, School of Medicine, The University of Adelaide; Affiliate Professor, School of Biological Sciences, The University of Adelaide; Adjunct Professor, School of Pharmacy and Medical Sciences, University of South Australia; Head, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Adelaide.
PROFESSOR SJOERD VAN DER BURG
Appointed to the MRAC in 2017. Advisor for the immunomonitoring of spontaneous and immune therapy induced immune responses at the Dutch Cancer Institute, Amsterdam, The Netherlands. Full professor in the immunotherapy of solid tumours at the University of Leiden. Head of the laboratory of Experimental Oncology of the departments of Clinical Oncology and Ophthalmology, Leiden University Medical Center, The Netherlands.
PROFESSOR DAVID CAMERON BA (HONS), DES, MA, MBBS, MRCP (UK), MSC, CCST, MD, FRCP EDIN.
Appointed to the MRAC in 2017. Professor of Oncology & Director of Cancer Services NHS Lothian, Edinburgh Cancer Research Centre, The University of Edinburgh.
PROFESSOR MICHELLE HABER AM, BSC (PSYCH) (HONS), PHD, HON DSC (UNSW), FAHMS
Appointed to the MRAC in 2012. Executive Director, Children’s Cancer Institute Australia, Sydney; Head of Program, Experimental Therapeutics; Conjoint Professor, Faculty of Medicine, University of NSW.
PROFESSOR GEOFF HILL MBCHB, MD, FRACP, FRCPA
Appointed to the MRAC in 2008. NHRMC Aust Fellow. Head, Division of Immunology at the QIMR Berghofer Medical Research Institute, Brisbane.
PROFESSOR DOUG HILTON BSC (HONS), PHD, FAA, FAHMS, FTSE, AO
Appointed to the MRAC in 2008. NHMRC Senior Principal Research Fellow. Director, Walter and Eliza Hall Institute; Head, Division of Molecular Medicine; Professor, The University of Melbourne; Member, Advisory Board, Medical Research Future Fund.
PROFESSOR PHILIP HOGG BSC (HONS), PHD UQ
Appointed to the MRAC in 2003. NHMRC Senior Principal Research Fellow; Director, ACRF Centenary Cancer Research Centre, The Charles Perkins Centre, University of Sydney.
PROFESSOR PAUL LAMBERT BS, PHD, POSTDOC
Appointed to the MRAC in 2014. Howard M Termin Professor of Oncology at the University of Wisconsin; Editorial Board Member of the Journal of Virology; Director, University of Wisconsin Cancer Biology Graduate Program, and Virology Training Program.
PROFESSOR ANGEL LOPEZ MBBS, PHD, FRCPA, FAA
Appointed to the MRAC in 2014. Director of the Centre for Cancer Biology; Head of Division of Human Immunology, Centre for Cancer Biology, Adelaide.
PROFESSOR JOHN RASKO AO, BSC(MED), MBBS(HONS), PHD, FFSC(RCPA), MAICD, FRCPA, FRACP, FAHMS
Appointed to the MRAC in 2016. Research Program Leader/Principal Investigator, Centenary Institute of Cancer Medicine and Cell Biology; Director and Head of Department, Department of Cell & Molecular Therapies, Royal Prince Alfred Hospital; Senior Staff Specialist in Gene Therapy and Haematology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney; Professor, Faculty of Medicine, University of Sydney; Approved Pathology Practitioner, Genea formerly Sydney IVF.
PROFESSOR JENNIFER STOW, BSC (HONS), PHD
Appointed to the MRAC in 2009. NHMRC Principal Research Fellow; Deputy Director (Research) and Group Leader, Cell Biology and Molecular Medicine Division, Centre for Inflammation and Disease Research, Institute for Molecular Bioscience, University of Queensland.
PROFESSOR JOSEPH A TRAPANI, PHD
Appointed to the MRAC in 2007. Executive Director of Cancer Research and Head of the Cancer Immunology Program at Peter MacCallum Cancer Centre, Melbourne. Head of The Sir Peter MacCallum Department of Oncology, The University of Melbourne.
PROFESSOR CONNIE TRIMBLE, MD
Appointed to the MRAC in 2014. Associate Professor of Gynecology, Obstetrics and Oncology, John Hopkins School of Medicine, Baltimore, USA. Diplomat of the American Board of Pathology and the American Board of Obstetrics and Gynecology; Fellow of the American Congress of Obstetricians and Gynecologists.
PROFESSOR MATHEW A VADAS AO, FAHMS, BSC, MB, BS, PHD, DSC
Executive Director, Centenary Institute of Cancer Medicine & Cell Biology; Professor of Medicine, University of Sydney, Central Clinical School.
PROFESSOR IAN FRAZER AC, FRS, FAA, MB, CHB (EDINBURGH), MD (MELBOURNE)
Appointed to the MRAC in 2005, Chairman 2009-2017. Professor, School of Medicine, The University of Queensland; Head, Cancer Immunology Program, UQDI; Board Chair, TRI Foundation; Chair, Advisory Board, Medical Research Future Fund.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.